ID   MVX-2
AC   CVCL_C3LY
SY   MaxiVaX-2; huGM-CSF clone 61.27; Clone #61.27
DR   Wikidata; Q116049838
RX   Patent=US20220265727;
RX   PubMed=36092361;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Culture Collection of Switzerland (CCOS); CCOS-1901.
CC   Characteristics: Expression of CSF2 is under the control of a PGK promoter (PubMed=36092361).
CC   Doubling time: 37 hours (Direct_author_submission).
CC   Transfected with: HGNC; 1773; CDK4.
CC   Transfected with: HGNC; 2434; CSF2.
CC   Transfected with: HGNC; 11730; TERT.
CC   Miscellaneous: Cell line name and doubling time from personal communication of Lathuiliere A.
CC   Derived from site: In situ; Muscle, semitendinosus; UBERON=UBERON_0001375.
CC   Cell type: Myoblast; CL=CL_0000056.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C3LX ! IHM-2
SX   Female
AG   32Y
CA   Telomerase immortalized cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   Patent=US20220265727;
RA   Lathuiliere A., Mach N., Salmon P.;
RT   "Immortalized myoblast cell lines and uses thereof.";
RL   Patent number US20220265727, 25-Aug-2022.
//
RX   PubMed=36092361; DOI=10.1016/j.omtm.2022.07.017;
RA   Lathuiliere A., Vernet R., Charrier E., Urwyler M., Von Rohr O.,
RA   Belkouch M.-C., Saingier V., Bouvarel T., Guillarme D., Engel A.,
RA   Salmon P., Laumonier T., Grogg J., Mach N.;
RT   "Immortalized human myoblast cell lines for the delivery of
RT   therapeutic proteins using encapsulated cell technology.";
RL   Mol. Ther. Methods Clin. Dev. 26:441-458(2022).
//